Hosted on MSN2h
Takeda broadens its deal with BridGene for up to $770mBridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...
GlobalData on MSN18h
EMA approves Takeda’s Takhzyro pre-filled pen option for HAEThe current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...
Takeda, a global biopharmaceutical company with a manufacturing site in Stanton Springs, unveiled its new Biomedical Waste ...
The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...
BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...
Takeda Pharmaceutical Stock Up 1.6 % Shares of Takeda Pharmaceutical stock opened at $14.08 on Friday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08 ...
Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback